ClinicalTrials.gg
CompletedNCT01085318Updated Feb 23, 2018Results posted

Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial

A Phase 4 interventional study of Rebif in Multiple Sclerosis, sponsored by EMD Serono. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-02-23.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
38
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing Interferon beta-1a in Multiple Sclerosis — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis.

Enrollment
21st of 34
38 · median 85
Started
2010
with 1 other
Phase 4
15 of 34
none open now
Registered
23rd of 34
by date
Lead sponsor
2 of 34
EMD Serono

Among the 34 studies testing Interferon beta-1a in Multiple Sclerosis, this one is the 21st largest by enrollment, is one of 2 that started in 2010, is one of 15 in phase 4, and was the 23rd registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

None of the 34 studies testing Interferon beta-1a in Multiple Sclerosis is open now. The open studies under Multiple Sclerosis, anywhere →

About Interferon beta-1a

Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 34 studies testing Interferon beta-1a in Multiple Sclerosis as a file.
02

Study summary

The purpose of this trial is to evaluate the effects of Rebif® 44 mcg subcutaneous (sc) three times a week (tiw) on a) remyelination/demyelination, b) lesion and brain volume, c) central nervous system (CNS) iron deposition, and d) immune status in subjects with relapsing-remitting multiple sclerosis (RRMS) RRMS via several MRI techniques.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects, 18-65 years of age, inclusive, at the time of signature
  2. RRMS diagnosed according to the McDonald criteria, treatment naïve or currently using any of the FDA-approved DMDs (excluding natalizumab (Tysabri®), mitoxantrone or Rebif®)
  3. Have a disease duration of up to twenty years
  4. Be willing and able to comply with the study procedures for the duration of the trial
  5. Have given written informed consent and signed Health Insurance Portability and Accountability Act (HIPAA) Authorization before any study- related activities are carried out
  6. Female subjects must not be either pregnant or breast-feeding and must lack , as defined by either:

The following inclusion criteria must be fulfilled by the Healthy Control subjects:

  1. Male and female subjects, 18-65 years of age, inclusive, at the time of informed consent signature
  2. Be willing and able to comply with the study procedures for the duration of the trial
  3. Have given written informed consent and signed Health Insurance Portability and Accountability Act (HIPAA) Authorization before any study- related activities are carried out
  4. Female subjects must not be either pregnant or breast-feeding and must lack childbearing potential, as defined by either:

Exclusion criteria

Exclusion Criteria:

  1. Have received treatment within three months prior to Screening with interferon-beta-1a (Rebif®), IVIG or plasmapheresis
  2. Have received treatment within thirty days prior to screening with agents (e.g. including but not limited to mitoxantrone, cyclophosphamide, cladribine, fludarabine, cyclosporine or total body irradiation) or any other concomitant immunomodulatory therapies (e.g., azathioprine, methotrexate, CellCept®, natalizumab, alemtuzumab/Campath and other immunomodulators/monoclonal agents)
  3. Have had a relapse within thirty days prior to the Screening Visit
  4. Have received treatment within thirty days prior to the initial MRI scan date at Study Day 1
  5. Have inadequate liver function, defined by a (ALT) > 2.5x (ULN), or alkaline phosphatase > 2.5x ULN, or total > 1.5x ULN
  6. Have inadequate bone marrow reserve, defined as a total white blood cell count \< 3.0x 109/L, count \< 75x109/L, \< 100g/L
  7. Have complete transverse myelitis or simultaneous-onset bilateral optic neuritis
  8. Have a history of alcohol or drug abuse
  9. Have thyroid dysfunction
  10. Have moderate to severe renal impairment
  11. Have a major medical or psychiatric illness that in the opinion of the investigator creates undue risk to the subject or could affect compliance with the study protocol
  12. Have a history of seizures not adequately controlled by treatment
  13. Have serious or acute cardiac disease, such as uncontrolled dysrhythmias, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled congestive heart failure
  14. Have, in the opinion of the investigator, any visual, physical or cognitive impairment that would preclude the subject from complying with the study protocol
  15. Have a known or allergy to interferon-beta or any of the
  16. Have received an drug or experimental procedure within the past thirty days
  17. Are pregnant or attempting to conceive

The following exclusion criteria must be fulfilled by the Healthy Control subjects:

  1. Have met any of the above noted criteria
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Active comparator
    Arm 1 MS Patients

    Rebif 44 tiw

    Drug: Rebif

  • No intervention
    Arm 2 Healthy Control

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Volume (in Millimeters Cubed) of Normal Appearing Brain Tissue (NABT) With Increasing (Indicative of Remyelination) Voxel-wise Magnetization Transfer Ratio (VW-MTR) From Baseline to 6 Months

    To characterize the effect of Rebif on remyelination using VW-MTR dynamic mapping of NABT in subjects ith RRMS over 6 months of treatment compared to a group of healthy Control (HC).

    Time frame: Baseline to Month 6

Secondary outcomes

  1. Change in Volume (in Millimeters Cubed) of Normal Appearing Brain Tissue (NABT) With Decreasing (Indicative of Demyelination) Voxel-wise Magnetization Transfer Ratio (VW-MTR)From Baseline to 6 Months

    To characterize the effect of Rebif on demyelination using VW-MTR dynamic mapping of NABT in subjects ith RRMS over 6 months of treatment compared to a group of healthy Control (HC).

    Time frame: Baseline to Month 6

Other outcomes

  1. Clinical Relapses

    Clinical Relapses

    Time frame: Over 6 months

  2. Time to First Clinical Relapse

    Time to First Clinical Relapse

    Time frame: Months

07

Results

Posted May 3, 2013

Participant flow

Recruitment took place at the clinic - June 16, 2010 through July 6, 2011

Participant flow — Overall Study
MilestoneArm 1 RRMS PatientsArm 2 Healthy Control
Started2315
Completed2115
Not completed20

Outcome measures

PrimaryChange in Volume (in Millimeters Cubed) of Normal Appearing Brain Tissue (NABT) With Increasing (Indicative of Remyelination) Voxel-wise Magnetization Transfer Ratio (VW-MTR) From Baseline to 6 Months

To characterize the effect of Rebif on remyelination using VW-MTR dynamic mapping of NABT in subjects ith RRMS over 6 months of treatment compared to a group of healthy Control (HC).

Time frame:
Baseline to Month 6
Reported as:
Median · mm^3
Change in Volume (in Millimeters Cubed) of Normal Appearing Brain Tissue (NABT) With Increasing (Indicative of Remyelination) Voxel-wise Magnetization Transfer Ratio (VW-MTR) From Baseline to 6 Months
mm^3Arm 1 RRMS PatientsArm 2 Healthy Control
Change in Volume (in Millimeters Cubed) of Normal Appearing Brain Tissue (NABT) With Increasing (Indicative of Remyelination) Voxel-wise Magnetization Transfer Ratio (VW-MTR) From Baseline to 6 Months1206.1 ± 4081.621342 ± 291.890
Statistical analysis
  • Arm 1 RRMS Patients vs Arm 2 Healthy Control · Wilcoxon (Mann-Whitney) · p = 0.061 · Median difference (final values): 864.1
SecondaryChange in Volume (in Millimeters Cubed) of Normal Appearing Brain Tissue (NABT) With Decreasing (Indicative of Demyelination) Voxel-wise Magnetization Transfer Ratio (VW-MTR)From Baseline to 6 Months

To characterize the effect of Rebif on demyelination using VW-MTR dynamic mapping of NABT in subjects ith RRMS over 6 months of treatment compared to a group of healthy Control (HC).

Time frame:
Baseline to Month 6
Reported as:
Median · mm^3
Change in Volume (in Millimeters Cubed) of Normal Appearing Brain Tissue (NABT) With Decreasing (Indicative of Demyelination) Voxel-wise Magnetization Transfer Ratio (VW-MTR)From Baseline to 6 Months
mm^3Arm 1 RRMS PatientsArm 2 Healthy Control
Change in Volume (in Millimeters Cubed) of Normal Appearing Brain Tissue (NABT) With Decreasing (Indicative of Demyelination) Voxel-wise Magnetization Transfer Ratio (VW-MTR)From Baseline to 6 Months941.99 ± 1262.565297 ± 311.269
Statistical analysis
  • Arm 1 RRMS Patients vs Arm 2 Healthy Control · Wilcoxon (Mann-Whitney) · p = <0.001 · Median difference (final values): 644.99
Other pre-specifiedClinical Relapses

Clinical Relapses

Time frame:
Over 6 months
Reported as:
Mean · relapses per participant
Clinical Relapses
relapses per participantArm 1 RRMS Patients
Clinical Relapses0.3 ± 0.88
Other pre-specifiedTime to First Clinical Relapse

Time to First Clinical Relapse

Time frame:
Months
Reported as:
Mean · months
Time to First Clinical Relapse
monthsArm 1 RRMS Patients
Time to First Clinical Relapse2.5 ± 1.88

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1 RRMS Patients—2/23 (8.7%)22/23 (95.7%)
Arm 2 Healthy Control—0/15 (0%)8/15 (53.3%)
Most frequent serious events
Most frequent serious events
EventArm 1 RRMS PatientsArm 2 Healthy Control
Multiple Sclerosis RelapseNervous system disorders1/230/15
Post procedural infectionInfections and infestations1/230/15
Most frequent other events
Showing 10 of 25
Most frequent other events
EventArm 1 RRMS PatientsArm 2 Healthy Control
Influenza like illnessGeneral disorders9/230/15
Injection site reactionGeneral disorders8/230/15
Multiple sclerosis relapseNervous system disorders5/230/15
FatigueGeneral disorders4/230/15
Injection site painGeneral disorders4/230/15
NasopharyngitisInfections and infestations4/232/15
HeadacheNervous system disorders3/230/15
MigraineNervous system disorders3/230/15
Muscular weaknessMusculoskeletal and connective tissue disorders3/230/15
NauseaGastrointestinal disorders3/230/15

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm 1 RRMS PatientsArm 2 Healthy ControlTotal
<=18 years000
Between 18 and 65 years231538
>=65 years000
Age, Continuous
Age, Continuous(years)Arm 1 RRMS PatientsArm 2 Healthy ControlTotal
Mean39.9 ± 10.1736.7 ± 10.3138.6 ± 10.21
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1 RRMS PatientsArm 2 Healthy ControlTotal
Female14822
Male9716
Region of Enrollment
Region of Enrollment(participants)Arm 1 RRMS PatientsArm 2 Healthy ControlTotal
United States231538
08

Study locations

1 site
  • EMD Serono, Inc.
    Rockland, Massachusetts 02370, United States
09

References and documents

Publications

  • Dwyer MG, Zivadinov R, Tao Y, Zhang X, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Weinstock-Guttman B, Hayward B, Dangond F, Markovic-Plese S. Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial. BMC Neurol. 2015 Nov 11;15:232. doi: 10.1186/s12883-015-0488-9. PubMed 26559139 ↗
  • Zivadinov R, Dwyer MG, Markovic-Plese S, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Hayward B, Dangond F, Weinstock-Guttman B. Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study. PLoS One. 2014 Mar 13;9(3):e91098. doi: 10.1371/journal.pone.0091098. eCollection 2014. PubMed 24625687 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2010 to primary completion in Feb 2012, 19 months.

Results were first posted in May 2013, 1 year 2 months after primary completion.

Of 36 industry-sponsored phase 4 interventional studies under Multiple Sclerosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 37. This study's 19 months is below that.

Counting every sponsor, half of 69 studies reached it within 34 months; a quarter within 23 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2010
First posted
Mar 11, 2010
StartActual
Jun 30, 2010
Primary completionActual
Feb 29, 2012
CompletionActual
Mar 31, 2012
Results first posted
May 3, 2013
Last update
Feb 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01085318
Lead sponsor
EMD Serono
Responsible party
Sponsor
First posted
Mar 11, 2010
Start date
Jun 30, 2010
Primary completion
Feb 29, 2012
Completion
Mar 31, 2012
Results posted
May 3, 2013
Last update
Feb 23, 2018

Study contacts

Fernando Dangond, MD
study director · EMD Serono
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon beta-1a

Start the discussion